1. Home
  2. CYRX vs MYGN Comparison

CYRX vs MYGN Comparison

Compare CYRX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CYRX

CryoPort Inc.

HOLD

Current Price

$9.95

Market Cap

419.3M

Sector

Health Care

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.91

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYRX
MYGN
Founded
1999
1991
Country
United States
United States
Employees
1100
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
419.3M
444.2M
IPO Year
2008
1996

Fundamental Metrics

Financial Performance
Metric
CYRX
MYGN
Price
$9.95
$4.91
Analyst Decision
Strong Buy
Buy
Analyst Count
9
7
Target Price
$12.94
$7.64
AVG Volume (30 Days)
406.1K
1.3M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
156.22
N/A
EPS
1.40
N/A
Revenue
$176,177,000.00
$771,400,000.00
Revenue This Year
$11.06
$6.89
Revenue Next Year
$8.45
$5.35
P/E Ratio
$6.89
N/A
Revenue Growth
N/A
2.33
52 Week Low
$5.21
$3.76
52 Week High
$11.45
$8.59

Technical Indicators

Market Signals
Indicator
CYRX
MYGN
Relative Strength Index (RSI) 70.69 54.92
Support Level $9.18 $4.23
Resistance Level $10.23 $5.67
Average True Range (ATR) 0.42 0.27
MACD 0.19 0.03
Stochastic Oscillator 88.01 87.97

Price Performance

Historical Comparison
CYRX
MYGN

About CYRX CryoPort Inc.

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: